IP Library Granted Patent US 8,796,212
Granted Patent B2
US 8,796,212 · App. 13/186,165 · Granted Aug 5, 2014

Composition and method for delivery of BMP-2 amplifier/co-activator for enhancement of osteogenesis

Inventors: Paul O. Zamora (Gaithersburg, MD); Brent Lee Atkinson (Frederick, MD); Xinhua Lin (Plainview, NY); Louis A. Pena (Poquott, NY)
Assignee: BioSurface Engineering Technologies, Inc.
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,796,212
App. No.
13/186,165
Granted
Aug 5, 2014
Kind
B2
Abstract

A composition comprising a synthetic growth factor analog comprising a non-growth factor heparin binding region, a linker and a sequence that binds specifically to a cell surface receptor and an osteoconductive material where the synthetic growth factor analog is attached to and can be released from the osteoconductive material and is an amplifier/co-activator of osteoinduction.

Claims (63)

1. A compound of formula II

wherein:

X is SEQ ID NO: 7;

R 1 is hydrogen (H—), such that the terminal group is —NH 2 ;

R 6 is a lysine;

R 5 is a lysine;

R 4 is —NH 2 at the carboxyl terminal group;

Y is Ahx-Ahx-Ahx wherein Ahx is 6-aminohexanoic acid; and

Z is SEQ ID NO: 5.

2. A composition comprising:

a compound of formula II

wherein:

X is SEQ ID NO: 7;

R 1 is hydrogen (H—), such that the terminal group is —NH 2 ;

R 6 is a lysine;

R 5 is a lysine;

R 4 is —NH 2 at the carboxyl terminal group;

Y is Ahx-Ahx-Ahx wherein Ahx is 6-aminohexanoic acid;

Z is SEQ ID NO: 5; and

an osteoconductive material comprising one or more of an inorganic material, a synthetic polymer, a natural polymer, or an allograft bone,

wherein the compound of formula II is attached to and can be released from the osteoconductive material.

3. The composition of claim 2 wherein the osteoconductive material is selected from hydroxyapatite, tricalcium phosphate, collagen, hyaluronate, calcium sulfate, polyglycolic acid fibers, polylactic-co-glycolic acid, allograft, and any combination thereof.

4. The composition of claim 2 wherein the osteoconductive material is formed into a granule, a putty, a powder, a gel, a block or a combination thereof.

5. A kit comprising:

a lyophilized vial of, with or without excipients, a compound of formula II

wherein:

X is SEQ ID NO: 7;

R 1 is hydrogen (H—), such that the terminal group is —NH 2 ;

R 6 is a lysine;

R 5 is a lysine;

R 4 is —NH 2 at the carboxyl terminal group;

Y is Ahx-Ahx-Ahx wherein Ahx is 6-aminohexanoic acid;

Z is SEQ ID NO: 5; and

a container of osteoconductive material.

6. A method for treating a bone lesion comprising:

coating an osteoconductive material with a compound of formula II having the following structure

wherein:

X is SEQ ID NO: 7;

R 1 is hydrogen (H—), such that the terminal group is —NH 2 ;

R 6 is a lysine;

R 5 is a lysine;

R 4 is —NH 2 at the carboxyl terminal group;

Y is Ahx-Ahx-Ahx wherein Ahx is 6-aminohexanoic acid; and

Z is SEQ ID NO: 5,

to generate a coated osteoconductive material with the compound of formula II releasably attached thereto; and

implanting the coated osteoconductive material in the bone lesion; wherein the osteoconductive material comprising one or more of an inorganic material, a synthetic polymer, or an allograft bone.

7. The method of claim 6 wherein an exogenous or recombinant bone growth factor is added to the osteoconductive material.

8. The method of claim 6 wherein the osteoconductive material is formed from granules, polymers, powders, gel, cement, putty or any combination thereof.

9. The method of claim 6 wherein the method further comprises adding host bone chips or bone marrow aspirate to the osteoconductive material.

10. The method of claim 6 wherein releasing the compound is rate-controlled by manipulating the composition of the osteoconductive material, the concentration of the compound attached to the osteoconductive material, or the physical properties of the osteoconductive material.

11. The method of claim 6 wherein the osteoconductive material is used in combination with a load bearing device to treat the bone lesion.

12. The method of claim 11 wherein the load bearing device is selected from cages, wedges, rods, pedicle screws, vertebral body replacement, intervertebral body fusion device, and rings for bone fusion.

13. The method of claim 11 wherein the treatment of the bone lesion results in spine fusion.

14. A method for treating a bone lesion comprising:

administering to a vertebrate subject in need of such treatment an effective amount of a compound of formula II

wherein:

X is SEQ ID NO: 7;

R 1 is hydrogen (H—), such that the terminal group is —NH 2 ;

R 6 is a lysine;

R 5 is a lysine;

R 4 is —NH 2 at the carboxyl terminal group;

Y is Ahx-Ahx-Ahx wherein Ahx is 6-aminohexanoic acid; and

Z is SEQ ID NO: 5.

Assignments (5)
CONFIRMATORY LICENSE Recorded Jul 13, 2026
From: BROOKHAVEN SCIENCE ASSOCIATES, LLC
To: U. S. DEPARTMENT OF ENERGY
Reel/Frame 075253/0071 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 10, 2015
From: FERRING INTERNATIONAL CENTER S.A.
To: FERRING B.V.
Reel/Frame 036062/0499 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 2, 2015
From: BIOSURFACE ENGINEERING TECHNOLOGIES, INC.
To: FERRING INTERNATIONAL CENTER S.A.
Reel/Frame 035769/0122 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 6, 2015
From: PENA, LOUIS A.; LIN, XINHUA
To: BROOKHAVEN SCIENCE ASSOCIATES, LLC
Reel/Frame 034910/0587 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 13, 2011
From: ZAMORA, PAUL O.; ATKINSON, BRENT LEE
To: BIOSURFACE ENGINEERING TECHNOLOGIES, INC.
Reel/Frame 026897/0134 →
Continuity (7)
Division 11767391 · Jun 22, 2007
Continuation In Part 11064039 · Feb 22, 2005
Continuation In Part 10644703 · Aug 19, 2003
Continuation In Part 10224268 · Aug 20, 2002
Provisional Application 60805594 · Jun 22, 2006
Provisional Application 60547012 · Feb 20, 2004
Related Publication 20110305741A1 · Dec 15, 2011